177 related articles for article (PubMed ID: 28463992)
1. Small molecule inhibitors of mesotrypsin from a structure-based docking screen.
Kayode O; Huang Z; Soares AS; Caulfield TR; Dong Z; Bode AM; Radisky ES
PLoS One; 2017; 12(5):e0176694. PubMed ID: 28463992
[TBL] [Abstract][Full Text] [Related]
2. The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity.
Salameh MA; Soares AS; Hockla A; Radisky DC; Radisky ES
Biochem J; 2011 Nov; 440(1):95-105. PubMed ID: 21806544
[TBL] [Abstract][Full Text] [Related]
3. Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors.
Salameh MA; Soares AS; Alloy A; Radisky ES
Protein Sci; 2012 Aug; 21(8):1103-12. PubMed ID: 22610453
[TBL] [Abstract][Full Text] [Related]
4. PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.
Hockla A; Miller E; Salameh MA; Copland JA; Radisky DC; Radisky ES
Mol Cancer Res; 2012 Dec; 10(12):1555-66. PubMed ID: 23258495
[TBL] [Abstract][Full Text] [Related]
5. Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.
Alloy AP; Kayode O; Wang R; Hockla A; Soares AS; Radisky ES
J Biol Chem; 2015 Aug; 290(35):21523-35. PubMed ID: 26175157
[TBL] [Abstract][Full Text] [Related]
6. Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.
Pendlebury D; Wang R; Henin RD; Hockla A; Soares AS; Madden BJ; Kazanov MD; Radisky ES
J Biol Chem; 2014 Nov; 289(47):32783-97. PubMed ID: 25301953
[TBL] [Abstract][Full Text] [Related]
7. Engineering potent mesotrypsin inhibitors based on the plant-derived cyclic peptide, sunflower trypsin inhibitor-1.
de Veer SJ; Li CY; Swedberg JE; Schroeder CI; Craik DJ
Eur J Med Chem; 2018 Jul; 155():695-704. PubMed ID: 29936356
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin.
Salameh MA; Soares AS; Hockla A; Radisky ES
J Biol Chem; 2008 Feb; 283(7):4115-23. PubMed ID: 18077447
[TBL] [Abstract][Full Text] [Related]
9. Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors.
Szmola R; Kukor Z; Sahin-Tóth M
J Biol Chem; 2003 Dec; 278(49):48580-9. PubMed ID: 14507909
[TBL] [Abstract][Full Text] [Related]
10. Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance.
Nyaruhucha CN; Kito M; Fukuoka SI
J Biol Chem; 1997 Apr; 272(16):10573-8. PubMed ID: 9099703
[TBL] [Abstract][Full Text] [Related]
11. PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.
Ma H; Hockla A; Mehner C; Coban M; Papo N; Radisky DC; Radisky ES
Sci Rep; 2019 Feb; 9(1):1844. PubMed ID: 30755669
[TBL] [Abstract][Full Text] [Related]
12. PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine.
Radisky ES
Asian J Androl; 2013 Jul; 15(4):439-40. PubMed ID: 23503422
[No Abstract] [Full Text] [Related]
13. The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.
Salameh MA; Robinson JL; Navaneetham D; Sinha D; Madden BJ; Walsh PN; Radisky ES
J Biol Chem; 2010 Jan; 285(3):1939-49. PubMed ID: 19920152
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of 2-guanidinyl pyridines and their trypsin inhibition and docking.
Ahmed Al-Hadhrami N; Ladwig A; Rahman A; Rozas I; Paul G Malthouse J; Evans P
Bioorg Med Chem; 2020 Aug; 28(16):115612. PubMed ID: 32690267
[TBL] [Abstract][Full Text] [Related]
15. Structural binding evidence of the trypanocidal drugs berenil and pentacarinate active principles to a serine protease model.
Perilo CS; Pereira MT; Santoro MM; Nagem RA
Int J Biol Macromol; 2010 Jun; 46(5):502-11. PubMed ID: 20356563
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.
Cohen I; Kayode O; Hockla A; Sankaran B; Radisky DC; Radisky ES; Papo N
Biochem J; 2016 May; 473(10):1329-41. PubMed ID: 26957636
[TBL] [Abstract][Full Text] [Related]
17. Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin.
Cohen I; Coban M; Shahar A; Sankaran B; Hockla A; Lacham S; Caulfield TR; Radisky ES; Papo N
J Biol Chem; 2019 Mar; 294(13):5105-5120. PubMed ID: 30700553
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of mesotrypsin by chymotrypsin C prevents trypsin inhibitor degradation.
Toldi V; Szabó A; Sahin-Tóth M
J Biol Chem; 2020 Mar; 295(11):3447-3455. PubMed ID: 32014997
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure reveals basis for the inhibitor resistance of human brain trypsin.
Katona G; Berglund GI; Hajdu J; Gráf L; Szilágyi L
J Mol Biol; 2002 Feb; 315(5):1209-18. PubMed ID: 11827488
[TBL] [Abstract][Full Text] [Related]
20. Mesotrypsin Signature Mutation in a Chymotrypsin C (CTRC) Variant Associated with Chronic Pancreatitis.
Szabó A; Ludwig M; Hegyi E; Szépeová R; Witt H; Sahin-Tóth M
J Biol Chem; 2015 Jul; 290(28):17282-92. PubMed ID: 26013824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
